Skip to Content

BAY 73-4506/15982: A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib

Objective
This is a clinical trial of investigational drug Regorafenib which will be administered orally.
IRB Protocol Number
13-2135
Principal Investigator(s)
WILLIAM TOM PURCELL

Cancer Trials

  • Digestive System Cancer
Sponsor(s)
Bayer Corporation
Contact
JAMIE BENDRICK-PEART at 720-848-0600
or JAMIE.BENDRICK-PEART@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period will determine eligibility. The length of time you will be in the study depends on your response to the study drug. Each cycle is 28 days long. You will take the study drug for 3 weeks but not during week 4. Every month after you finish the study drug, we will contact you to see how you are doing and to see if you have started any new treatments. This study will involve collection of medical and disease history, ECG, blood draws, CT and MRI of the chest, abdomen and pelvis to determine the location and size of your cancer. The study doctor will request participant's permission to obtain medical information, including CT and/or MRI scans, and liver tissue samples, if available, from other doctors and hospitals previously treated. // Eligibility criteria include but are not limited to 18 years or older with hepatocellular carcinoma (HCC) after sorafenib. Participants must have adequate bone marrow, liver and renal function.